NUVB Stock — Nuvation Bio Inc.: Cash, EV, Pipeline

Share price

$6.08

Market cap

$2,133.1M

Cash

$661.0M

Enterprise value

$1,720.6M

Balance sheet

Cash	$661.0M
Debt	$248.5M
Net cash	$412.5M
Enterprise value	$1,720.6M
Basic shares	346.5M shares
Fully diluted shares	646.4M shares
Fully diluted market cap	$3,930.4M
Cash per share	$1.91

Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.

Price history

Loading NUVB daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Mar 16 - Apr 27	Taletrectinib	Phase 1	Healthy Adult Participants	—
Apr 12 - May 24	NUV-1511	Phase 2	Advanced Solid Tumor; HER2-negative Breast Cancer; Metastatic Castration-resistant Prostate Cancer (mCRPC)	—
Jan 12 - Feb 23	safusidenib	Phase 3	Glioma; Astrocytoma, Grade IV; IDH1-mutant Glioma	—
Feb 12 - Mar 26	Taletrectinib	Phase 3	Non Small Cell Lung Cancer	—
Jun 12 - Jul 24	Safusidenib	Phase 3	Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutatio; Astrocytoma IDH Mutant Grade 2; Oligodendroglioma	—
Oct 11 - Nov 22	Taletrectinib	Phase 3	Non-small Cell Lung Cancer (NSCLC)	—
Oct 13 - Nov 24	Safusidenib	Phase 2	Grade 2 IDH1-mutant Glioma; Grade 3 IDH1-mutant Glioma; Glioma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

taletrectinib

Approved · Active Modality: small molecule (oral ROS1 inhibitor)

Aliases IBTROZI, AB-106, DOVBLERON (China)

Target ROS1

Partnerships Daiichi Sankyo (in-license): global rights ($8M milestone on US approval). Innovent: China/Taiwan ($12M reg milestones; up to $17M + $105M milestones; mid-teens to low-twenties royalties). Nippon Kayaku: Japan ($40M upfront + $25M reg milestone; low-mid double-digit royalties). Eisai: EU + 40+ territories (€50M upfront ~$58.7M; up to €145M milestones; up to high-teens royalties)

Indications

ROS1-positive NSCLC, locally advanced or metastatic (Approved)
Resected ROS1+ early-stage NSCLC (adjuvant) (Phase 3)

Status note FDA approved June 11, 2025; approved in Japan (MHLW, Sep 2025) and China (NMPA); US launch June 2025. FDA Orphan Drug Designation; Breakthrough Therapy (FDA + NMPA). EMA and UK MAA validated (Mar 2026, Jun 2026). Phase 2 TRUST-I/TRUST-II, confirmatory Phase 3 TRUST-III vs crizotinib (China), global Phase 3 TRUST-IV adjuvant.

safusidenib

Phase 3 · Active Modality: small molecule (oral, brain-penetrant)

Target mutant IDH1 (mIDH1)

Partnerships Daiichi Sankyo: exclusive global development/commercialization rights (license amended Apr 2026 to include Japan; $3M milestone paid Feb 2026 on SIGMA conversion to pivotal; $0.5M for Japan amendment)

Indications

IDH1-mutant astrocytoma, high-risk features (maintenance) (Phase 3)
Grade 2 IDH1-mutant glioma (ex-US) (Phase 3)
Grade 2/3 IDH1-mutant glioma progressed after vorasidenib (US) (Phase 2)

Status note SIGMA randomized Phase 3 vs placebo converted to pivotal study. July 2026 announcement of two new studies: pivotal Phase 3 in grade 2 IDH1-mutant glioma (ex-US) and Phase 2 in post-vorasidenib US patients.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	safusidenib
Lead indication	Glioma
Lead phase	Phase 3
Active trials	9
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05303519	Phase 3	Recruiting	Sponsor	NUVB	—	Glioma; Astrocytoma, Grade IV; IDH1-mutant Glioma	—
NCT06564324	Phase 3	Recruiting	Sponsor	NUVB	—	Non Small Cell Lung Cancer	—
NCT07712757	Phase 3	Not yet recruiting	Sponsor	NUVB	—	Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutatio; Astrocytoma IDH Mutant Grade 2; Oligodendroglioma	—
NCT07154706	Phase 3	Recruiting	Sponsor	NUVB	—	Non-small Cell Lung Cancer (NSCLC)	—
NCT06334432	Phase 2	Active, not recruiting	Sponsor	NUVB	—	Advanced Solid Tumor; HER2-negative Breast Cancer; Metastatic Castration-resistant Prostate Cancer (mCRPC)	—
NCT07703436	Phase 2	Not yet recruiting	Sponsor	NUVB	—	Grade 2 IDH1-mutant Glioma; Grade 3 IDH1-mutant Glioma; Glioma	—
NCT04395677	Phase 2	Active, not recruiting	Sponsor	NUVB	—	Non Small Cell Lung Cancer	—
NCT04919811	Phase 2	Active, not recruiting	Sponsor	NUVB	—	Non Small Cell Lung Cancer	—
NCT07742384	Phase 1	Not yet recruiting	Sponsor	NUVB	—	Healthy Adult Participants	—
NCT04151342	Not disclosed	Recruiting	Collaborator	University Health Network, Toronto	AMGN, AZN, TAK	Cancer; Malignancies Multiple; Malignant Solid Tumor	—

Sponsor-matched active trials from ClinicalTrials.gov (9 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 10 active trials for Nuvation Bio Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	0	-43,500	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

NUVB — Nuvation Bio Inc.